|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
MET, a receptor tyrosine kinase for hepatocyte growth factor, is associated with tumor progression and acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI).
|
21733594 |
2012 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Epidermal growth factor receptor (EGFR) and Cortactin are molecular markers that are important in tumour progression and development, and interact within the EGF pathway.
|
29201160 |
2017 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Cripto, the founding member of the EGF-CFC genes, plays an essential role in embryo development and is involved in cancer progression.
|
25629528 |
2015 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Due to the interaction between HER2 and other ErbB receptors, HER2 is implicated in the EGF family of ligands-regulated tumor progression.
|
23542467 |
2013 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Variations in the DNA sequence of the gene EGF can lead to alterations in EGF activity, which is suspected to influence tumor progression.
|
19921131 |
2009 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Several oncogenes, e.g., the epithelial growth factor receptor (EGF-R), and tumor-suppressor genes, e.g., the p53 gene, have been found to correlate significantly with tumor progression.
|
8806198 |
1996 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our studies reveal a crucial link of EGF receptor to NF-κB activation and tumor progression.
|
27991920 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, our findings suggest that AQP3 is required for EGF-EGFR cell signaling in cancer cells and is a therapeutic target for cancer progression.
|
26896765 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Consequently, it is not unexpected that EMT has profound impacts on the neoplastic progression, patient survival, as well as the resistance of cancers to therapeutics (taxol, vincristine, oxaliplatin, EGF-R targeted therapy and radiotherapy), independent of the "classical" resistance mechanisms linked to genotoxic drugs.
|
18718806 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The EGF family growth factor HB-EGF is synthesized in cancer cells and plays pivotal roles in oncogenic transformation and tumor progression, but the contribution of HB-EGF expressed in tumor stromal cells to tumor growth remains unclear.
|
20190463 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that EGF and TPA may share only 1 class of receptors, and that TPA may be used to monitor cancer progression.
|
6118206 |
1981 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The results suggest that proHB-EGF may play an important role in tumor progression.
|
23349913 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The over-expression of epidermal growth factor receptor (EGFR) and its ligands, epidermal growth factor (EGF) and transforming growth factor-alpha, is a common feature of epithelial carcinomas and correlates with neoplastic progression.
|
15642791 |
2005 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Epidermal growth factor (EGF) plays a critical role in malignant transformation of hepatocytes and tumor progression.
|
23419149 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.
|
16818638 |
2006 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy.
|
25915843 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
|
28088463 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression.
|
24346967 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that HB-EGF secreted from KRas-mutated colorectal cancer cells promotes IMF migration through ERK and JNK activation, which, in turn, could support cancer progression.
|
28339087 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
At later stages of tumor progression, epithelial carcinogenesis is associated with transition to a mesenchymal phenotype, which may contribute to the more aggressive properties of cancer cells and may be stimulated by growth factors such as epidermal growth factor and transforming growth factor-beta.
|
18790770 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The understanding of the significance of EGF-related growth factors in tumor progression provides a framework for a biological approach to the therapy of human gastrointestinal carcinomas.
|
2157713 |
1990 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
However, Epidermal Growth Factor (EGF) promotes tumor progression even with significant EGR1 upregulation.
|
30845713 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results indicate that EGF may affect claudins and tight junctional functions in ovarian cancer cells during cancer progression.
|
22544349 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
This phenomenon may be attributed to the cross talk between TGF-β signaling and other pathways, including EGF receptor (EGFR) signaling during cancer progression.
|
29215776 |
2018 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
EGF receptor (EGFR) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kinase receptors that have been implicated in diverse cellular processes and as regulators of several microRNAs (miRNAs), thus contributing to tumor progression.
|
23650389 |
2013 |